Given her focus on thoracic oncology, Naidoo’s expertise in pneumonitis is particularly vital. Lung cancer patients often have pre-existing lung damage from smoking, COPD, or prior radiation. Her 2017 study in the Journal of Clinical Oncology delineated the incidence, clinical course, and management of checkpoint-inhibitor pneumonitis, noting that it occurs in 3-5% of monotherapy patients but up to 10% with combination therapy. She further stratified risk by histology (squamous vs. adenocarcinoma) and prior radiation fields. This granularity allows oncologists to weigh therapeutic benefit against respiratory risk—a life-or-death calculation for patients with limited pulmonary reserve.
In the high-stakes ecosystem of Hollywood, the spotlight usually finds the directors, the screenwriters, and the A-list talent. But behind the most thought-provoking, socially conscious, and commercially viable films of the last decade stands a quiet force: Jarushka Ross. jarushka ross
While her name may not be as universally recognized as the stars she works with, within the industry, Jarushka Ross has become synonymous with integrity, diversity, and artistic excellence. As the founder and CEO of Now Entertainment, Ross has carved out a unique niche: producing high-quality, mainstream films that prioritize representation without sacrificing the bottom line. Given her focus on thoracic oncology, Naidoo’s expertise
This article delves into the career, philosophy, and impact of Jarushka Ross, exploring how she transitioned from legal advocacy to becoming one of the most influential producers of her generation. She further stratified risk by histology (squamous vs
In the landscape of modern oncology, few names are as closely tied to the practical management of immunotherapy as Dr. Jarushka Naidoo (formerly published as Jarushka Ross). While many scientists focused on expanding the indications for checkpoint inhibitors, Naidoo recognized a critical bottleneck in patient survival: toxicity. As a medical oncologist and researcher at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and a consultant at Beacon Hospital in Dublin, she has become the world’s leading authority on immune-related adverse events (irAEs). Her work has shifted the paradigm from simply activating the immune system to controlling it—ensuring that patients die with their cancer, not from the cure.